Skip to main content

Table 3 Comparison of flare and non-flare group in SACQ and SQCQ

From: Treatments and outcomes in Chinese patients with serologically active clinically quiescent systemic lupus erythematosus: a retrospective observational study

  SACQ (170) SQCQ (187)
Flare (56) Non-flare (114) p Flare (29) Non-flare (158) p
Age at diagnosis (years) 30.95 ± 13.88 32.65 ± 14.61 0.469 34.19 ± 14.14 39.42 ± 15.15 0.086
Gender (male to female) 8:48 13:101 0.624 2:27 17:141 0.765
Recurrence time or follow-up timea (months) 21.82 (13.39, 31.59) 19.23 (10.02, 34.32) 0.440 26.43 (16.72, 41.97) 22.92 (11.63, 43.65) 0.361
Duration of serological activity/inactivity before SACQ/SQCQ (months) 13.58 (6.94, 25.19) 15.49 (7.31, 25.87) 0.771 11.10 (5.77, 21.72) 8.88 (3.01, 15.99) 0.115
Time to SACQ/SQCQb (months) 23.88 (13.03, 50.68) 22.07 (12.16, 50.62) 0.562 21.0 (11.85, 58.65) 17.28 (9.84, 36.53) 0.241
Dose of corticosteroids at the start of SACQ/SQCQ 7.5 (5.0, 7.5) 7.5 (6.25, 7.5) 0.096 7.5 (5.0, 7.5) 7.5 (5.0, 7.5) 0.608
Taking antimalarials at the start of SACQ/SQCQ 40/56 (71.4%) 90/114 (78.9%) 0.277 22/29 132/158 0.319
Taking immunosuppressants at the start of SACQ/SQCQ 29/56 (51.8%) 67/114 (58.8%) 0.414 15/29 84/158 0.886
Dose of corticosteroidsc (mg) when relapsed or at the end of follow-up 5.0 (2.81,7.5) 3.75 (1.25, 5.0) 0.011 5.0 (0, 5.0) 3.75 (1.25, 5.0) 0.489
Taking antimalarials when relapsed or at the end of follow-up 36/56 (64.3%) 97/114 (85.1%) 0.002 17/29 (58.6%) 135/158 (85.4%) 0.001
Taking immunosuppressants when relapsed or at the end of follow-up 23/56 (41.1%) 69/114 (60.5%) 0.017 10/29 (34.5%) 87/158 (55.1%) 0.041
Anti-dsDNA (+) 41/56 (73.2%) 96/114 (84.2%) 0.101 — — —
Hypocomplementemia 26/56 (46.4%) 36/114 (31.6%) 0.064 — — —
Symptoms at initial diagnosis.
 LN 16/56 (28.6%) 46/114 (40.4%) 0.175 10/29 (34.5%) 58/158 (36.7%) 0.819
 NPSLE 2/56 (3.6%) 6/114 (5.3%) 1.000 1/29 (3.4%) 10/158 (6.3%) 0.860
 Thrombocytopenia 9/56 (16.1%) 14/114 (12.3%) 0.485 6/29 (20.7%) 30/158 (19.0%) 0.831
 Hemolytic anemia 5/56 (8.9%) 9/114 (7.9%) 0.776 1/29 (3.4%) 13/158 (8.2%) 0.606
 Pulmonary hypertension 3/56 (5.4%) 1/114 (0.9%) 0.105 1/29 (3.4%) 4/158 (2.5%) 1.000
 Myocardial involvement 0/56 (0) 0/114 (0) NA 0/29 (0) 3/158 (1.9%) 1.000
 ILD 2/56 (3.6%) 1/114 (0.9%) 0.253 0/29 (0) 6/158 (3.8%) 0.622
 Alveolar hemorrhage 0/56 (0) 0/114 (0) NA 0/29 (0) 0/29 (0) NA
 Smooth muscle involvement 0/56 (0) 6/114 (5.3%) 0.179 0/29 (0) 5/158 (3.2%) 0.730
 Polyserositis 2/56 (3.6%) 6/114 (5.3%) 1.000 1/29 (3.4%) 7/158 (4.4%) 1.000
 APS 2/56 (3.6%) 5/114 (4.4%) 1.000 1/29 (3.4%) 4/158 (2.5%) 1.000
 TTP or TMA 0/56 (0) 0/114 (0) NA 0/29 (0) 0/29 (0) NA
 Secondary SS 5/56 (8.9%) 14/114 (12.3%) 0.611 3/29 (10.3%) 22/158 (13.9%) 0.823
  1. aThe period from the time they reached the SACQ/SQCQ to the time of recurrence (flare group) or at the end of follow-up (non-flare group)
  2. bThe period from the onset of SLE to the time they reached SACQ
  3. cCorticosteroid doses were converted to milligrams (mg) of prednisone equivalent
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us